Nationality Australian | Occupation Biomedical engineer | |
 | ||
Employer Australian Institute for Bioengineering and Nanotechnology | ||
Mark Kendall (born 1972) is an Australian biomedical engineer and innovator. He is a Professor of the Australian Institute for Bioengineering and Nanotechnology. His field of research is the delivery of immunotherapeutics to the skin without the use of a needle or syringe.
Biography
Kendall was born in 1972. He graduated from University of Queensland, where he began his engineering studies in 1990. In 1998, he started working as a University Research Lecturer in Engineering Science at the University of Oxford. He returned to Brisbane in 2006 and became a researcher at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN). In 2011, he co-founded the development company Vaxxas with an investor syndicate. The company's technology, called Nanopatch, is intended to serve as a needle-free vaccine delivery device. In 2011, Kendall and his AIBN team received the Australian Research Council Eureka Prize for Excellence in Research by an Interdisciplinary Team. In 2012, he was awarded the Rolex Awards for Enterprise for his "pioneering efforts to expand knowledge and improve human life".